In the US alone, monitoring has found that GLP-1 analogue use in people with type 2 diabetes and atherosclerotic cardiovascular disease nearly doubled, rising from 5.2% in 2018 to 9.9% in 2022 [3]. Here, GLP1R is linked to type 2 diabetes mellitus.